SRRK Share Price | Scholar Rock Holding Corp. Stock Analysis & Recommendation

Q: What does Scholar Rock Holding Corp. do?

Overview:Scholar Rock Holding Corporation is a biopharmaceutical company engaged in the development of monoclonal antibodies for the treatment of diseases such as neuromuscular disorders, cancer, fibrosis, and anemia, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot:Most recent Net Profit: -75 Million (Quarterly Results - Mar 2025) Market cap: USD 2,957.55 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.99 Return on Equity: -84.58% Price to Book: 9.47Contact Details:Address: 620 Memorial Dr Fl 2, CAMBRIDGE MA: 02139-4815 Tel: ['1 857 2593860', '1 917 601-1649'] Fax: 1 302 6555049 Website: https://scholarrock.com/

Q: Is Scholar Rock Holding Corp. overvalued or undervalued?

As of 9 May 2023, Scholar Rock Holding Corp. has moved from a valuation grade of risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued given its troubling financial ratios, including a Price to Book Value of 10.41 and an EV to EBIT of -10.86, which suggest that the market is pricing in expectations that are not supported by its current earnings or asset performance. Furthermore, the Return on Capital Employed (ROCE) is alarmingly low at -8470.74%, reflecting severe inefficiencies in capital utilization.In comparison to its peers, Scholar Rock's valuation metrics are less favorable; for instance, Avidity Biosciences has a P/E ratio of -9.5851 and an EV to EBITDA of -5.0262, while Janux Therapeutics shows a P/E of -17.5680 and an EV to EBITDA of -3.1688. These comparisons highlight that Scholar Rock's financial health is significantly worse than its competitors in the sector. Despite a strong one-year stock return of 293.85% compared to the S&P 500's 10.26%, the underlying financial metrics suggest that the stock is not justified at its current price of 33.28, reinforcing the conclusion that it is overvalued.

Q: Is Scholar Rock Holding Corp. technically bullish or bearish?

As of 26 September 2025, the technical trend for Scholar Rock Holding Corp. has changed from mildly bearish to sideways. Currently, the overall stance is neutral, with mixed signals across different indicators. The weekly MACD is mildly bearish, while the monthly MACD is bullish. The Bollinger Bands indicate bullish momentum on both weekly and monthly time frames. Daily moving averages are mildly bearish, and the KST shows a similar pattern with a weekly mild bearish and monthly bullish stance. The Dow Theory reflects no trend on the weekly chart and mildly bearish on the monthly chart. The OBV is mildly bullish weekly but mildly bearish monthly.In terms of performance, the stock has shown strong returns over the past year, gaining 347.98%, significantly outperforming the S&P 500's 15.64% return. However, year-to-date, it has underperformed with a return of -10.34% compared to the S&P 500's 12.96%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.63 M

Shareholding (Dec 2025)

FII

32.57%

Held by 140 FIIs

DII

Held by 116 DIIs

Promoter

29.19%

How big is Scholar Rock Holding Corp.?

22-Jun-2025

As of Jun 18, Scholar Rock Holding Corp. has a market capitalization of $2.96 billion, with net sales of $0.00 million and a net profit of -$264.16 million over the last four quarters. The balance sheet shows shareholder's funds of $368.63 million and total assets of $474.92 million.

View full answer

What does Scholar Rock Holding Corp. do?

22-Jun-2025

Scholar Rock Holding Corporation is a biopharmaceutical company focused on developing monoclonal antibodies for treating neuromuscular disorders, cancer, fibrosis, and anemia. It has a market cap of approximately $2.96 billion and reported a net profit loss of $75 million as of March 2025.

View full answer

Who are in the management team of Scholar Rock Holding Corp.?

22-Jun-2025

As of March 2022, the management team of Scholar Rock Holding Corp. includes Mr. David Hallal as Independent Chairman, Mr. Tony Kingsley as President and CEO, and independent directors Ms. Kristina Burow and Dr. Michael Gilman.

View full answer

Is Scholar Rock Holding Corp. overvalued or undervalued?

25-Jun-2025

As of May 9, 2023, Scholar Rock Holding Corp. is considered overvalued with troubling financial ratios and a significant decline in its valuation grade, indicating severe inefficiencies and worse financial health compared to its peers, despite a strong one-year stock return.

View full answer

Is Scholar Rock Holding Corp. technically bullish or bearish?

29-Sep-2025

As of September 26, 2025, Scholar Rock Holding Corp. shows a neutral technical trend with mixed signals, having gained 347.98% over the past year but underperformed year-to-date with a return of -10.34% compared to the S&P 500's 12.96%.

View full answer

Compare Scholar Rock Holding Corp. with Similar Stocks

Aerovate Therapeutics, Inc.Nautilus Biotechnology, Inc.iTeos Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 4,625 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.08

Return on Equity

-144.26%

Price to Book

18.88

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-91 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-4.86%

6 Months

29.36%

1 Year

32.1%

2 Years

166.38%

3 Years

407.08%

4 Years

207.68%

5 Years

-22.05%

Scholar Rock Holding Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-224.17%

EBIT to Interest (avg)

-137.33

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.99

Sales to Capital Employed (avg)

0.10

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

18.88

EV to EBIT

-12.04

EV to EBITDA

-12.10

EV to Capital Employed

-221.36

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-144.26%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 65 Schemes (100%)

Foreign Institutions

Held by 140 Foreign Institutions (32.57%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 10.96% vs 7.09% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-91.50",
          "val2": "-103.10",
          "chgp": "11.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.50",
          "val2": "1.30",
          "chgp": "92.31%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-91.00",
          "val2": "-102.20",
          "chgp": "10.96%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -53.43% vs -48.55% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-383.00",
          "val2": "-250.10",
          "chgp": "-53.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "6.90",
          "val2": "6.80",
          "chgp": "1.47%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-377.90",
          "val2": "-246.30",
          "chgp": "-53.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ

Dec'25

Sep'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-91.50

-103.10

11.25%

Interest

2.50

1.30

92.31%

Exceptional Items

0.00

Consolidate Net Profit

-91.00

-102.20

10.96%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Sep 2025

Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 10.96% vs 7.09% in Sep 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-383.00

-250.10

-53.14%

Interest

6.90

6.80

1.47%

Exceptional Items

0.00

Consolidate Net Profit

-377.90

-246.30

-53.43%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -53.43% vs -48.55% in Dec 2024

All Annual Results

Company CV

About Scholar Rock Holding Corp.

Scholar Rock Holding Corp.

Pharmaceuticals & Biotechnology

Scholar Rock Holding Corporation is a biopharmaceutical company. The Company is engaged in the development of monoclonal antibodies for treatment of diseases, such as neuromuscular disorders, cancer, fibrosis, and anemia. The Company's lead product candidate is SRK-015 that is in its pre-clinical stage of development. SRK-015 is a selective inhibitor of the activation of the growth factor myostatin in skeletal muscle. It is used to treat spinal muscular atrophy (SMA). The Company also develops other antibody programs that include TGFβ1 and BMP6. The TGFβ1 antibody program is focused on the development of antibodies that are specific inhibitors of TGFβ1 members.

Company Coordinates

Company Details

620 Memorial Dr Fl 2 , CAMBRIDGE MA : 02139-4815

Tel: 1 857 25938601 917 601-1649

https://scholarrock.com/

Registrar Details